when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

REGENERON PHARMACEUTICALS, INC. ($REGN) · catalysts · pharmadog

← back to REGENERON PHARMACEUTICALS, INC.

Catalysts for $REGN

74 tracked

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

EVKEEZA (EVINACUMAB-DGNB) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

EVKEEZA (EVINACUMAB-DGNB) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

PRALUENT (ALIROCUMAB) — FDA approval

LIBTAYO (CEMIPLIMAB-RWLC) — FDA approval

DUPIXENT (DUPILUMAB) — FDA approval

← prevpage 2 of 3next →

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%

$REGN837.46+1.31%